User:Z5088434: Difference between revisions
No edit summary |
No edit summary |
||
| Line 12: | Line 12: | ||
Summary of Article I: <ref><pubmed>26193891</pubmed></ref> | Summary of Article I: <ref><pubmed>26193891</pubmed></ref> | ||
PMID 26193891 | PMID 26193891 | ||
Revision as of 17:26, 13 August 2015
--Mark Hill (talk) 17:16, 5 August 2015 (AEST) Well done, you were first! We will be talking more about this in the Practical on Friday.
Please do not use your real name on this website, use only your student number.
- 2015 Course: Week 2 Lecture 1 Lecture 2 Lab 1 | Week 3 Lecture 3 Lecture 4 Lab 2 | Week 4 Lecture 5 Lecture 6 Lab 3 | Week 5 Lecture 7 Lecture 8 Lab 4 | Week 6 Lecture 9 Lecture 10 Lab 5 | Week 7 Lecture 11 Lecture 12 Lab 6 | Week 8 Lecture 13 Lecture 14 Lab 7 | Week 9 Lecture 15 Lecture 16 Lab 8 | Week 10 Lecture 17 Lecture 18 Lab 9 | Week 11 Lecture 19 Lecture 20 Lab 10 | Week 12 Lecture 21 Lecture 22 Lab 11 | Week 13 Lecture 23 Lecture 24 Lab 12 | 2015 Projects: Three Person Embryos | Ovarian Hyper-stimulation Syndrome | Polycystic Ovarian Syndrome | Male Infertility | Oncofertility | Preimplantation Genetic Diagnosis | Students | Student Designed Quiz Questions | Moodle page
Glossary Links
- Glossary: A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | Numbers | Symbols | Term Link
Lab Attendance
--Z5088434 (talk) 13:46, 7 August 2015 (AEST)
Lab 1 - Online Assessment
Summary of Article I: [1]
PMID 26193891
The aim of the prospective, self-controlled study was to investigate the impact of low-dose growth hormone (GH) supplementation for patients undergoing in vitro fertilization (IVF) with poor ovarian response (POR), which is defined as IVF incidence rates between 9 and 24%. GH is known to participate in follicular development by regulating gonadotropins in granulosa cells which in turn regulate the synthesis of IGF-I. This growth factor plays a major role in the synthesis of sex steroids and, thus, oocyte maturation. GH has been administered to POR patients since the 1990s, however, with mixed results. Therapeutic advantages were only established in women of advanced reproductive age. A possible reason for this unsuccessful administration is proposed to be the GH dose; the majority of doses used for POR patients is equal to those used in patients with GH-deficiency. However, POR patients are usually not GH-deficient, which leads to the investigation of the effects of lower dose GH supplementation to POR patients.
Method:
Results:
References
PMID 26193891
- ↑ <pubmed>26193891</pubmed>
